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Background: Transient ischemic attacks (TIA) are characterized by acute onset focal neurological symptoms and
complete recovery within 24 hours. Attacks of nonfocal symptoms not fulfilling the criteria for TIA but lacking a
clear alternative diagnosis are called transient neurological attacks (TNA). Although TIA symptoms are transient in
nature, cognitive complaints may persist. In particular, attacks consisting of both focal and nonfocal symptoms
(mixed TNA) have been found to be associated with an increased risk of dementia. We aim to study the prevalence,
etiology and risk factors of cognitive impairment after TIA or TNA.
Methods/Design: CONNECT is a prospective cohort study on cognitive function after TIA and TNA. In total, 150
patients aged ≥45 years with a recent (<7 days after onset) TIA or TNA and no history of stroke or dementia will be
included. We will classify events as: TIA, nonfocal TNA, or mixed TNA. Known short lasting paroxysmal neurological
disorders like migraine aura, seizures and Ménière disease are excluded from the diagnosis of TNA. Patients will
complete a comprehensive neuropsychological assessment and undergo MRI <7 days after the qualifying event
and again after six months. The primary clinical outcomes will be cognitive function at baseline and six months
after the primary event. Imaging outcomes include the prevalence and evolution of DWI lesions, white matter
hyperintensities and lacunes, as well as resting state networks functionality and white matter microstructural
integrity. Differences between types of event and DWI, as well as determinants of both clinical and imaging
outcomes, will be assessed.
Discussion: CONNECT can provide insight in the prevalence, etiology and risk factors of cognitive impairment after
TIA and TNA and thereby potentially identify a new group of patients at increased risk of cognitive impairment.
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Transient ischemic attacks (TIAs) are characterized by
acute onset focal neurological symptoms of vascular ori-
gin that resolve completely within 24 hours [1]. Often
patients are encountered with a myriad of acute onset
and short-lasting nonfocal symptoms, which do not ful-
fill the criteria for TIA and might have another cause
than focal cerebral ischemia. In the absence of a clear al-
ternative cause, these attacks are referred to as transient* Correspondence: ewoud.vandijk@radboudumc.nl
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unless otherwise stated.neurological attacks (TNAs) [2]. TNAs are almost as
prevalent as TIAs, but their etiology is unknown [3].
In contrast to the definition of TIA, which states
symptom resolution within 24 hours, many patients re-
port cognitive problems afterwards [4]. In addition, par-
ticularly patients with a TNA or a mixture of focal and
nonfocal symptoms (mixed TNA) have an increased risk
of dementia [5].
Diffusion-weighted imaging (DWI) studies show signs
of cytotoxic edema beyond the point of symptom reso-
lution in 30% of TIA patients [6]. Cerebrovascular dam-
age, even in the absence of clinical signs of stroke, mayal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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crostructural integrity and functional connectivity are
associated with worse cognitive performance [10,11].
The influence of DWI lesions and other cerebrovascular
damage on the cognitive outcome of TNA patients is
unknown, In addition, the cognitive profile of TIA and
TNA patients is unclear.
Previous studies on cognitive function after TNA are
scarce and have focused almost exclusively on TIA pa-
tients [12-14]. These were mostly cross-sectional studies,
without brain imaging and information on previous
cerebrovascular events. Furthermore, cognitive testing
was often performed several months to years after the
initial event. Since the risk of new stroke is highest
shortly after TIA, a delay in testing can influence cogni-
tive results [15].
Establishing a relationship between TIA or TNA and
cognitive decline could identify a group of patients at
risk of cognitive impairment and dementia and provides
an opportunity to clarify how transient neurological
symptoms relate to lasting cognitive consequences. By
widening the scope beyond TIA to ‘TNAs’ with nonfocal
and mixed symptoms, the previously described but not
understood association between TNA and worse cogni-
tive outcome can be prospectively investigated. Finally,
performing brain imaging in these patients could pro-
vide insight in the early developmental mechanisms of
dementia.
We therefore set up the Cohort study ON Neuroimaging,
Etiology and Cognitive consequences of Transient neuro-
logical attacks (CONNECT); a prospective cohort study
on cognitive function and its determinants in patients
with a TIA or TNA and aged ≥45 years.Methods/Design
Study design
CONNECT is a prospective cohort study on the cognitive
function of patients with a TIA or TNA and aged ≥45 years.
Patient recruitment takes place at a university hospital and
a large regional nonacademic hospital. The Medical Review
Ethics Committee region Arnhem-Nijmegen approved the
study (NL31651.091.10) and written informed consent is
obtained from all participants.Objectives
The primary objective of our study is to determine the
course and profile of cognitive function and the causes
of cognitive impairment after TIA and TNA, and its re-
lationship with DWI abnormalities. Secondary objectives
are to determine the prevalence and course of subjective
cognitive complaints, depressive symptoms, fatigue and
sleep disorders and their effect on cognitive outcome in
patients with TIA or TNA.Study population
All consecutive patients referred to the specialized TIA
clinics of the Radboud university medical center and the
Rijnstate Hospital will be screened for eligibility. Patients
with a final diagnosis of TIA or TNA within seven days
after onset and aged ≥45 years at the time of the quali-
fying event are considered eligible for participation. TIA
is defined as a sudden onset focal loss of brain function
of vascular origin with complete resolution of focal
symptoms within 24 hours [1]. TNA is defined as an
attack of sudden nonfocal neurological symptoms that
completely resolve within 24 hours, without clear evi-
dence for migraine, epilepsy, Ménière disease, hyperven-
tilation, cardiac syncope, hypoglycaemia, or orthostatic
hypotension [5]. In order to minimize the influence of
concomitant neurological disorders on cognitive func-
tion, the following exclusion criteria will be applied:
1. Prior stroke with clinical symptoms.
2. Prior diagnosis of dementia.
3. Intracerebral space-occupying lesion.
4. Prior neurological disease which can influence
cognitive function (e.g. Parkinson’s disease, multiple
sclerosis).
5. Inability to undergo MRI.
Prior TIA and TNA are not a reason for exclusion.
Procedures
Eligible patients will be recruited at specialized TIA
clinics. We intend to include 150 patients and expect to
complete inclusion over a 3-year period. Patients formally
enter the study after informed consent and written ap-
proval. Baseline assessments will take place during admis-
sion to the TIA clinic at the participating center and
follow-up is performed six months later at the Radboud
university medical center and Donders Institute for Brain,
Cognition and Behaviour. Baseline and follow-up assess-
ments are summarized in Table 1.
Sample size and power calculation
The sample size is based on the ability to detect a diffe-
rence in average cognitive performance between the
three patient groups, expressed as z-score, equal to 0.5
standard deviation. With a power of 80% and a type-I
error rate of 0.1, we need 50 patients per group to iden-
tify this difference.
Assessments - baseline
All patients referred to the TIA clinic are analyzed and
treated according to a dedicated TIA protocol, which in-
cludes investigations as recommended in international
guidelines [16].
Table 1 Schedule of assessments
Assessment Baseline Follow-up
Demographics
Age, sex X
Education X
Working status X
Marital status X
Structured assessment of TIA/TNA
presentation
Duration of symptoms X
Number of episodes in week
before inclusion
X
Focal symptoms* X
Nonfocal symptoms* X
Incident focal symptoms* X
Incident nonfocal symptoms* X
Medical history
Hypertension X X
Dyslipidemia X X
Diabetes mellitus X X
Atrial fibrillation X X
Other cardiovascular diseases† X
First-degree relatives with
cardiovascular disease
X
Smoking status X X
Alcohol consumption X X
Drug abuse X X
Hypercoagulability X
Acute infection X
Migraine X
Previous TIA/TNA X
Carotid endarterectomy X X
Epilepsy X X
Depression X X
Current medication use X X
Incident cardiovascular events† X
Incident TIA, cerebral infarction
or hemorrhage
X
Physical examination
Length and weight, BMI X
Blood pressure X
Neurological examination X
ECG
(Paroxysmal) atrial fibrillation X
Ischemia X
Left ventricular hypertrophy X
Table 1 Schedule of assessments (Continued)
Fasting laboratory investigations
Glucose X
Lipid profile X
Creatinine X
Neuropsychological assessment
Global cognitive function
Mini Mental State Examination X
Frontal Assessment Battery X X
Episodic memory
Rey Auditory Verbal Learning Test X X
Executive function
Verbal fluency X X
Stroop Color Word Test
(interference score)
X X
Brixton Spatial Anticipation Test X X
Information processing speed
Symbol-Digit Modalities Test X X
Stroop Color Word Test (Cards I and II) X X
Attention
Verbal Series Attention Test X X
Subjective cognitive failures
Cognitive failures Questionnaire X X
Depressive symptoms
Hospital Anxiety and Depression Scale X X
Sleep disorders
Scales for Outcomes in Parkinson’s
Disease - Sleep
X X
Fatigue
Checklist on Individual Strength X X
Prior cognitive performance
Informant Questionnaire on Cognitive
Decline in the Elderly
X X
MRI
Anatomical sequences (T1, T2, FLAIR, T2*) X X
Diffusion-weighted imaging X
MR angiography X
Susceptibility-weighted imaging X
Diffusion tensor imaging X
Resting-state functional MRI X
Empty cells indicate no assessment. BMI indicates body-mass index; FLAIR,
fluid-attenuated inversion recovery; TNA, transient neurological attack;
ToF, time-of-flight.
*Presence of 18 predefined symptoms, both focal and nonfocal (see also Table 2).
†Myocardial infarction, coronary artery bypass grafting, percutaneous
transluminal coronary angioplasty, valvular heart disease and peripheral
revascularization procedures.
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We will obtain a detailed history of the signs and symp-
toms of the qualifying event. The patient’s own account
of events is noted, after which a structured interview
consisting of 18 questions about the presence of specific
neurological symptoms (nine focal and nine nonfocal
symptoms, Table 2) will be administered. These symp-
toms are derived from the latest classification of the
National Institute of Neurological Disorders and Stroke
and previous research on nonfocal TNAs [1,5]. The du-
ration of symptoms and number of episodes in the week
before presentation are also recorded.
Demographics and medical history
Standardized, structured questionnaires will be used to
obtain information on demographics and level of edu-
cation (classified using seven categories, in accordance
with the Dutch educational system: 1 being less than pri-
mary school and 7 reflecting an academic degree) [17].
The presence of established and potential stroke risk
factors as classified by the American Heart Association
will be determined by standardized, structured question-
naires [18]. Established risk factors include age, sex,
history of cardiovascular disease in first-degree relatives,
hypertension, dyslipidemia, diabetes mellitus, smoking,
atrial fibrillation and cardiovascular disease (myocardial
infarction, coronary artery bypass grafting, percutaneous
transluminal coronary angioplasty, valvular heart disease
and peripheral revascularization procedures). Potential
risk factors include alcohol consumption (excess con-
sumption defined as an intake of >200 g of pure alcohol
per week), drug abuse, hypercoagulability, acute infec-
tion, a history of migraine, and the use of oral contra-
ceptives. In addition, all patients will be asked about a
history of TIA, carotid endarterectomy, epilepsy, and de-
pression. Current medication use is recorded and classi-
fied according to the Anatomical Therapeutic Chemical
(ATC) classification system (World Health Organization,Table 2 Structured assessment of transient focal and
nonfocal neurological symptoms
Focal Nonfocal
Hemiparesis Decreased consciousness or
unconsciousness
Hemihypesthesia Confusion
Dysphasia Amnesia
Dysarthria Unsteadiness
Hemianopia Nonrotatory dizziness
Transient monocular blindness Positive visual phenomena
Hemiataxia Paresthesias
Diplopia Bilateral weakness of arms or legs
Vertigo Unwell feelings
All symptoms should have a sudden onset, rapid clearance and last <24 hours.WHO Collaborating Centre for drug statistics and meth-
odology, http://www.whocc.no/atcddd/).
Physical examination
All patients will undergo a neurological examination.
Blood pressure will be measured in a supine position
after five minutes of rest. The average of three measure-
ments will be used for analysis. Hypertension is defined
as a systolic blood pressure ≥135 mmHg and/or a dia-
stolic blood pressure ≥85 mmHg and/or the use of blood
pressure-lowering medication.
Neuropsychological assessment
Participants will undergo an extensive neuropsycho-
logical assessment covering the main cognitive domains.
Neuropsychological tests are administered by a trained
examiner in a quiet, well-lit room and under standard
circumstances. The Mini-Mental State Examination and
Frontal Assessment Battery are used as screening tools
for global cognitive function and executive function,
respectively [19,20]. The three-trial version of the Rey
Auditory Verbal Learning Test (RAVLT) will be applied
to assess verbal episodic memory. This test also includes
delayed free-recall and recognition trials [21]. To evalu-
ate executive function three tests will be used; a verbal
fluency test (naming as many animals and professions
within 60 seconds each; response generation), the inter-
ference score of the abbreviated Stroop Color Word Test
(response inhibition), and the Brixton Spatial Anticipation
Test (rule detection) [22,23]. Information processing
speed will be tested with the Symbol-Digit Modalities Test
and Cards I and II of the abbreviated Stroop Color Word
Test [24,25]. Attention is measured with the Verbal Series
Attention Test [26].
In addition to cognitive tests, patients will complete
several self-report questionnaires. Subjective cognitive
failures will be registered with the modified Cognitive
Failures Questionnaire (CFQ) [27]. Both nighttime sleep
and daytime sleepiness will be assessed with the Scales for
Outcomes in Parkinson’s Disease - Sleep, and the presence
of depressive symptoms with the Hospital Anxiety and
Depression Scale [28,29]. Furthermore, patients will fill
out the Checklist on Individual Strength, a validated ques-
tionnaire on fatigue [30]. Finally, cognitive function prior
to the qualifying event will be assessed by asking relatives
to complete the Informant Questionnaire on Cognitive
Decline in the Elderly (IQCODE) [31].
Ancillary investigations
MRI protocol All included patients will undergo MRI
of the brain as well as MR angiography of the carotid
and vertebral arteries. MRI scanning will be performed
on a 1.5-Tesla Magnetom Scanner (Siemens, Erlangen,
Germany). The scanning protocol of the brain includes
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532/10 ms; flip angle 90°; voxel size 0.8 × 0.6 × 5.0 mm);
transversal fluid-attenuated inversion recovery (FLAIR)
pulse sequence (TR/TE/T1 9000/108/2500 ms; voxel
size 0.9 × 0.7 × 5.0 mm), transversal T2-weighted turbo spin
echo sequence (TR/TE 5010/98 ms; voxel size 0.6 × 0.4 ×
5.0 mm), transversal T2*-weighted gradient echo sequence
(TR/TE 727/19.1 ms; voxel size 1.0 × 0.7 × 5.0 mm), and
single-shot echo planar diffusion-weighted sequence (TR/
TE 6300/134 ms; EPI factor 192; voxel size 1.2 × 1.2 ×
5.0 mm) with diffusion weighting applied in three direc-
tions and a b-value of 1000 s/mm2. The scanning protocol
of the cerebropetal vessels includes three-dimensional
time-of-flight (ToF), phase contrast angiography (PCA),
transversal T1-, T2- and proton density weighted se-
quences. Furthermore, a maximum intensity projection
ToF and PCA will be reconstructed. The complete scan-
ning protocol takes approximately 30 minutes. All cere-
bropetal vessel studies will be assessed for the presence
and degree of stenosis by an experienced neuroradiologist.
Electrocardiogram A conventional 12-lead electrocar-
diogram (ECG) will be performed and assessed by an ex-
perienced physician. The presence of atrial fibrillation,
prior myocardial infarction and left ventricular hyper-
trophy is noted for every patient. In case of doubt a car-
diologist is consulted for expertise.
Vena puncture Fasting blood samples will be taken and
analysis will include glucose, lipid profile and creatinine.
Classification of TNA
Three experienced stroke neurologists will indepen-
dently adjudicate qualifying events as TIA, nonfocal TNA,
or mixed TNA, based on the complete description of signs
and symptoms as provided by the patient, the presence or
absence of specific focal and nonfocal neurological symp-
toms, and the medical history. Fifty case descriptions will
be assigned to each possible pair of classifying neurolo-
gists, such that each event is independently adjudicated by
two specialists. In case of disagreement a consensus mee-
ting including the third stroke neurologist will be held.
The classifying neurologists will be blinded to the results
of neuropsychological tests, brain imaging studies, or any
other ancillary investigations. An attack containing at least
one focal neurological symptom will be classified as TIA
or mixed TNA, depending on the presence of additional
nonfocal symptoms. When only nonfocal symptoms are
present, the event is categorized as nonfocal TNA.
Assessments - follow-up
Six months after baseline all patients are contacted for
follow-up. In case of inability or unwillingness to undergo
(part of) the follow-up investigations, the reasons arerecorded. Follow-up measurements are summarized in
Table 1.
Incident events
Patients will be asked whether they have experienced
any of the 18 predefined neurological symptoms bet-
ween baseline and follow-up (Table 2). Symptoms had to
develop within seconds to minutes, last less than
24 hours and disappear completely. Reported symptoms
are evaluated for these features by an investigator.
In addition, a standardized, structured questionnaire
will be administered to determine the occurrence of new
cardiovascular events between baseline and follow-up.
Whenever an event is suspected, additional information
on the exact date of diagnosis, treating physician and
initiated therapies will be gathered. When necessary, the
treating physician will be contacted for further informa-
tion. All suspected events will be evaluated and adjudi-
cated by a medical specialist trained in the specific field.
The following items are assessed: TIA, ischemic and
hemorrhagic stroke, myocardial infarction, coronary ar-
tery bypass graft, percutaneous transluminal coronary
angioplasty, and carotid endarterectomy.
Neuropsychological assessment
A comprehensive neuropsychological assessment cover-
ing the main cognitive domains will be performed under
the same conditions as baseline. To minimize material-
specific learning effects, parallel versions are used for
the verbal fluency task (items of clothing and fruit) and
the RAVLT.
Subjective cognitive failures occurring between base-
line and follow-up will be assessed with the modified
CFQ. The presence of depressive symptoms, fatigue and
sleep disturbances will be determined with the same
questionnaires as at baseline [27-30]. Patients are specif-
ically asked to reflect on the presence of these symptoms
in the last two weeks. Furthermore, the influence of cog-
nitive performance on daily functioning between base-
line and follow-up as experienced by relatives will be
determined by means of the IQCODE [31].
MRI protocol
MRI scanning at follow-up will be performed on a similar
1.5-Tesla Magnetom scanner (Siemens, Erlangen, Germany)
as baseline. The scanning protocol consists of the following:
whole brain 3-dimensional T1 magnetization-prepared
rapid gradient-echo (MPRAGE) sequence (TR/TE/T1
2730/2.95/1000 ms; flip angle 7°; voxel size 1.0 × 1.0 ×
1.0 mm), transversal FLAIR pulse sequence (TR/TE/T1
12220/85/2200 ms; voxel size 1.2 × 1.0 × 3.0 mm; slice gap
0.6 mm), transversal T2-weighted turbo spin echo se-
quence (TR/TE 7440/96 ms; voxel size 0.9 × 0.9 × 3.0 mm),
transversal T2*-weighted gradient echo sequence (TR/TE
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echo susceptibility weighted imaging sequence (TR/TE
49/40 ms; voxel size 0.8 × 0.7 × 1.0 mm), diffusion tensor
imaging (DTI) (TR/TE 9100/98 ms; voxel size 2.2 × 2.2 ×
2.2 mm; 7 unweighted scans, 61 diffusion weighted scans,
with non co-linear orientation of the diffusion weighting
gradient and b-value 1000 s/mm3), and resting state
imaging using a gradient echo EPI (TR/TE 1870/35 ms;
voxel size 3.5 × 3.5 × 3.0 mm; slice gap 0.5 mm). During
resting state, patients will be told to relax with their eyes
closed, without concentrating on anything particular.
The complete scanning protocol takes approximately
60 minutes.
Outcome measures
Clinical outcomes
The primary clinical outcome measure will be domain-
specific cognitive performance at baseline and six months
after the qualifying event. Raw cognitive test results at
baseline and follow-up will be transformed into z-scores,
based on the mean and standard deviation of the baseline
tests. Next, domain-specific compound scores will be
computed by averaging z-scores of tests assessing the
same cognitive domain. The compound score for global
cognitive function is the average of the z-scores of all tests
[32]. Other clinical outcomes will be incident vascular
events, subjective cognitive failures, fatigue, depressive
symptoms, and sleep disorders.
Imaging outcomes
Two experienced raters will evaluate both baseline and
follow-up brain MRI without knowledge of any clinical
information.
Signs of acute brain infarction A hyperintense lesion
on DWI with a corresponding hypointensity on the ap-
parent diffusion coefficient (ADC) map is considered
cytotoxic edema and therefore a sign of acute brain in-
farction. In case of disagreement a consensus meeting
will be held.
Lacunes of presumed vascular origin and territorial
infarcts A lacune is defined as a hypo-intensity on
T1-weighted and FLAIR images >2 mm and ≤15 mm,
ruling out enlarged perivascular spaces and infraputa-
minal pseudolacunes [33]. Territorial infarcts are defined
as hypo-intense lesions on T1-weighted images >15 mm,
with corresponding hyperintensity on FLAIR images
[33]. After rating the presence of lacunes and territorial
infarcts, clinical information regarding the qualifying,
previous or incident TNAs, or any incident stroke, will
be made available and the lesion will be categorized as
silent or symptomatic, based on the clinical symptomsand lesion location. In case of disagreement a consensus
meeting is held.
White matter hyperintensities of presumed vascular
origin White matter hyperintensities of presumed vas-
cular origin (WMH) are defined as hyperintense lesions
in the white matter on FLAIR, which are not or only
slightly hypointense on T1-weighted sequences [33].
Gliosis surrounding infarcts is not considered WMH.
Total WMH volume will be determined by an in-house
developed, validated technique.
Brain volumetry Probability maps for grey and white
matter and cerebrospinal fluid will be computed using a
six class segmentation tool in Statistical Parametric Map-
ping software (http://www.fil.ion.ucl.ac.uk/spm) (SPM 8)
on the T1 images. Total volumes of grey and white matter
are defined as the sum of all voxel volumes belonging to
that tissue class. Total brain volume is taken as the sum of
total grey and total white matter volume. After computa-
tion of co-registration parameters of the FLAIR image to
the T1 image, these are used to bring both the FLAIR and
WMH segmentation images into the patients anatomical
reference frame. Resulting images will be visually checked
for co-registration errors. Finally, WMH segmentations
are resampled to and combined with the white matter
probability maps, thus resulting in a WMH map (intersec-
tion of WMH and white matter) and normal-appearing
white matter map (complement of WMH in white matter)
in the T1 reference space.
Microbleeds Microbleeds are defined as small, homoge-
neous, round or ovoid, hypo-intense foci on T2*-
weighted images with a diameter of 2-10 mm [33]. Foci
are not considered to be microbleeds when they are
probable calcifications or iron deposits, symmetric hypo-
intensities in the globus pallidus, flow void artifacts of
pial blood vessels, or hypo-intense T2*-weighted signals
inside an infarct, which are likely to be hemorrhagic
transformation [34]. Microbleeds will be counted per
hemisphere separately and stratified into lobar, deep and
infratentorial lesions [34].
Diffusion tensor imaging An in-house developed algo-
rithm for patching artifacts from cardiac and head motion
will be used for preprocessing of diffusion data [35]. The
output of this Matlab (The Mathworks, Inc.) based pro-
gram comprises the tensor derivates fractional anisotropy
and mean diffusivity [36]. The mean unweighted image
will be used to determine the coregistration parameters
to the anatomical T1 image, which are then applied to
all diffusion-weighted images and results [37]. All im-
ages will be visually checked for motion artifacts and
coregistration errors.
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be processed according to previously published methods, in
order to gain motion corrected and spatially smoothed im-
ages with minimized effects of low and high non-neuronal
noise [38], which in turn will be used to determine func-
tional connectivity between different brain regions.
Analysis
In the first analyses cognitive domain-specific composite
z-scores are the outcome variables. Analysis of (co) va-
riance will be performed to test for differences in cognitive
performance at baseline and follow-up (using baseline
mean and SD as reference) between TIA, mixed, and non-
focal TNA patients, adjusting for known determinants of
cognitive function. The relationship between cognitive
function and DWI lesions will be determined, adjusting
for differences in other MRI parameters (WMH volume,
total brain volume, silent brain infarcts, microbleeds).
Analyses will be performed before and after exclusion of
patients with incident stroke during follow-up. Next,
multinominal logistic regression analysis will be used to
identify determinants of cognitive decline among demo-
graphics, type of event, MRI parameters and vascular risk
factors. Subsequently, the relationship between DTI pa-
rameters at follow-up and both explanatory determinants
and cognitive function will be determined. Finally, func-
tional connectivity will be compared between TIA, mixed,
and nonfocal TNA and between strata of cognitive
performance.
Discussion
CONNECT provides an opportunity to identify patients
who are not routinely included in cerebrovascular cohort
studies but who are potentially at risk of cognitive decline
[5]. The added value of our study to the current know-
ledge of cognition after TIA and TNA lies in the longi-
tudinal design and the combination of comprehensive
neuropsychological testing with both conventional and ad-
vanced neuroimaging. This could potentially provide more
clarity in the causes and mechanisms of decline in cogni-
tive function after short-lasting neurological deficits.
CONNECT may therefore contribute to the growing
notion that TIA is not just a warning sign but has lasting
consequences of its own, and identify TNA as a poten-
tial new group of patients at risk of cognitive decline.
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